It is assumed that the fair value cannot be reliably measured for a biological asset. This
hypothesis can be ignored only at the initial recognition of a biological asset, for which there
are not available prices or values determined on the market and for which the alternative
estimations of the fair value are not clearly reliable. In these cases, the biological assets will
be evaluated at cost less any cumulated depreciation and any loss from cumulated
depreciation. Once the fair value for such a biological asset can be measured reliably, an
entity will measure it at the fair value less the estimated point-of-sale costs. When an asset
meets the classification conditions as detained forsale according to IFRS 5, it is assumed that
the fair value can be reliably measured.